#ViiV Healthcare

Here are the top 20 philanthropic funders of HIV, according to an FCAA report, which also offers good news for the U.S. South and PrEP.

However, the regimen appears much less potent for those who aren’t virally suppressed.

In a recent trial, the investigational entry inhibitor helped fully suppress HIV in a majority of those with multidrug-resistant virus.

Spoken word artist Mary Bowman opened the 20th Community Summit with a gorgeous poem that manages to revisit decades of HIV/AIDS.

The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.

In clinical trials, the single-tablet regimen of Tivicay (dolutegravir) and Epivir (lamivudine) was as effective as a three-drug treatment.

The New Orleans–style event also honored three HIV advocates.

ViiV Healthcare has reported promising one-year findings from a study of a two-drug injectable treatment given every four weeks.

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

Researchers presented 100-week data on a trial of the antiretroviral (ARV) regimen at the international AIDS conference.

Full 48-week results comparing Tivicay plus Epivir with Tivicay plus Truvada were presented at the International AIDS Conference.

“As Much As I Can” debuted in the South. This week, it opens in Harlem, New York.

Forty-eight-week results are in from a Phase III study that switched participants from Triumeq to Gilead’s new single-tablet regimen.

ViiV alleges that the bictegravir component of the tablet infringes on its own patent for Tivicay (dolutegravir).

Who are the top 20 funders across the globe? This annual FCAA report lists them all.